Patrick R. O'Neil - 15 Jan 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: EVP CLO & General Counsel
Issuer ticker: IONS
Reported as of: 15 Jan 2026
Net transaction value: -$697,045
SEC form: 4
Accepted by SEC: 20 Jan 2026, 20:20:29 UTC
Prior SEC filing: 06 Jan 2026
Next SEC filing: 02 Feb 2026
Source filing: View source filing
Reporting owner signature: Patrick R. O'Neil

Key filing fact

Patrick R. O'Neil filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 20 Jan 2026.

Key facts

This page summarizes Patrick R. O'Neil's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 20 Jan 2026, 20:20.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: -$697,045.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001564926 Primary reporting owner

O'NEIL PATRICK R.

Relationship: EVP CLO & General Counsel
Address: 2855 GAZELLE COURT, CARLSBAD
Signature: Patrick R. O'Neil
Signature date: 20 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +21,473
Change %: +40%
Price: $0.000000
Shares after: 75,362
Date: 15 Jan 2026
Ownership: Direct
Footnotes: F1

IONS transaction

Common Stock

Sale

Transaction value: $697,045
Shares: -9,191
Change %: -12%
Price: $75.84
Shares after: 66,171
Date: 16 Jan 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Performance Restricted Stock Units

Award

Transaction value: $0
Shares: +25,800
Change %: +40%
Price: $0.000000
Shares after: 90,601
Date: 15 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,800
Exercise price: $0.000000
Footnotes: F4, F5

IONS transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -21,473
Change %: -35%
Price: $0.000000
Shares after: 39,251
Date: 15 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,473
Exercise price: $0.000000
Footnotes: F6, F7

IONS transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +9,675
Change %: +25%
Price: $0.000000
Shares after: 48,926
Date: 15 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,675
Exercise price: $0.000000
Footnotes: F6, F7, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

Footnote F2

The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.78 to $75.94 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

Footnote F4

Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

Footnote F5

The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

Footnote F6

Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

Footnote F7

Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

Footnote F8

Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.